Comparative and Pragmatic Study of Simponi Aria Versus Remicade in Rheumatoid Arthritis

Trial Profile

Comparative and Pragmatic Study of Simponi Aria Versus Remicade in Rheumatoid Arthritis

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 08 Nov 2017

At a glance

  • Drugs Golimumab (Primary) ; Infliximab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions
  • Acronyms AWARE
  • Sponsors Janssen
  • Most Recent Events

    • 08 Nov 2017 Interim analysis (n=747) results assessing the golimumab and Infliximab utilization patterns, presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting.
    • 17 Jun 2017 Interim anaysis results (n=353) presented at the 18th Annual Congress of the European League Against Rheumatism
    • 08 Mar 2017 Planned End Date changed from 1 Feb 2021 to 25 Feb 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top